Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 7/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12134728 | 0.83 | PIK3CG (0.33) | PIK3CG | |
| SCHEMBL22792590 | 0.83 | PIK3CG (0.33) | PIK3CG | |
| SCHEMBL12134965 | 0.83 | PIK3CG (0.33) | PIK3CG | |
| SCHEMBL3292267 | 0.78 | PIK3CG (0.47) | PIK3CGEGFR | |
| SCHEMBL1378685 | 0.75 | PIK3CG (0.46) | PIK3CGEGFR | |
| SCHEMBL25101246 | 0.74 | PIK3CG (0.34) | PIK3CGEGFRDGAT1 | |
| SCHEMBL26795835 | 0.74 | PIK3CG (0.34) | PIK3CGEGFRDGAT1 | |
| SCHEMBL30290978 | 0.72 | PIK3CG (0.41) | PIK3CGEGFR | |
| SCHEMBL2490862 | 0.72 | PIK3CG (0.41) | PIK3CGEGFR | |
| SCHEMBL22793044 | 0.72 | EGFR (0.34) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-7705014-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7589068-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090062327-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-7396832-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080009507-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149536-A1 | Inhibitors of Akt activity | AKT1, AKT2, AKT3 | PIK3CG 12/4885EGFR 412/4885DGAT1 2151/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | PIK3CG 370/4885EGFR 945/4885DGAT1 1456/4885 |
| US-20090062327-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885EGFR 455/4885DGAT1 1658/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | PIK3CG 361/4885EGFR 1014/4885DGAT1 1672/4885 |
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885EGFR 455/4885DGAT1 1658/4885 |
| US-20080009507-A1 | Inhibitors of Akt Activity | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885EGFR 455/4885DGAT1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.